Reporter Lee Yumi of Money Today.
2021.12.11


Evosonic (CEO Choi Jae-young), a healthcare source technology holder related to acoustic vibration, announced on the 9th that it will recently attract investment worth 3 billion won and develop electronic drugs.

Evosonic is a company that has focused on healthcare products using "sound vibration" rather than motors. Starting with beauty devices, the parts were commercialized by applying them to physical therapy devices for pain relief. Recently, he has developed massage chairs. The investment was made to newly enter the medical care market.

Based on the investment, the company will start developing electronic drugs related to dementia. Prior to this, Evosonic has been studying the field of nerve and cell regeneration using acoustic vibration with the Seoul National University Immunomedical Research Institute. In this process, we discovered the best way to stimulate sound waves that human dermal fiber cells, collagen, and mitochondria can activate.

Currently, medical devices related to dementia treatment are being developed in collaboration with AriBio, a dementia treatment company. It is a medical device equipped with a mechanism that can reduce the rate of development of dementia. The plan is to speed up approval and commercialization by being selected for the "authorization helper for new development medical devices" project operated by the Ministry of Food and Drug Safety.

The electronic drug market, called DTx (digital therapy), is drawing attention worldwide, said Choi Jae-young, CEO of Evosonic. "A plan has emerged to activate nerves and cells involved in aging with 'stimulating technology' rather than drugs or food." "Evosonic has derived a quantitative evaluation method for the impact of sound waves on the human body through a project to support small managers in Gangwon-do (materials, parts, and equipment)," he added. "We will prepare a 'global standard' with sound vibration technology."



Article